Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Clostridium novyi-NT with checkpoint blockade in solid tumors

Blessie Elizabeth Nelson • 17 Apr 2023
AACR 2023
General Antibodies Checkpoint Inhibitors Clostridium novyi-NT Pembrolizumab

Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of a Phase I trial (NCT03435952) of Clostridium novyi-NT (non-toxic) with pembrolizumab in patients with solid tumors. Clostridium novyi-NT is an attenuated form of C. novyi, which has shown to have antitumor properties. The study demonstrated promising clinical activity in patients irrespective of tumor type. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Blessie Elizabeth Nelson

Genomic landscape of metaplastic breast cancer in the AACR GENIE cohort
13:42
Genomic landscape of metaplastic breast cancer in the AACR GENIE cohort
Blessie Elizabeth Nelson • 28 Apr 2025
How does BRAF rechallenge and retreatment impact tumor histology beyond melanoma?
9:56
How does BRAF rechallenge and retreatment impact tumor histology beyond melanoma?
Blessie Elizabeth Nelson • 3 Jun 2023
Investigating the synergy between Clostridium novyi with pembrolizumab in solid tumors
4:12
Investigating the synergy between Clostridium novyi with pembrolizumab in solid tumors
Blessie Elizabeth Nelson • 3 Jun 2023
Intratumoral injection of Clostridium novyi-NT to enhance efficacy
1:19
Intratumoral injection of Clostridium novyi-NT to enhance efficacy
Blessie Elizabeth Nelson • 17 Apr 2023

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals